Literature DB >> 31965219

Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane.

Vicente Galiano1, José A Encinar2,3, José Villalaín4,5.   

Abstract

Bardoxolone methyl (CDDO-Me), a synthetic derivative of the naturally occurring triterpenoid oleanolic acid, displays strong antioxidant, anticancer and anti-inflammatory activities, according to different bibliographical sources. However, the understanding of its molecular mechanism is missing. Furthermore, CDDO-Me has displayed a significant cytotoxicity against various types of cancer cells. CDDO-Me has a noticeable hydrophobic character and several of its effects could be attributed to its ability to be incorporated inside the biological membrane and therefore modify its structure and specifically interact with its components. In this study, we have used full-atom molecular dynamics to determine the location, orientation and interactions of CDDO-Me in phospholipid model membranes. Our results support the location of CDDO-Me in the middle of the membrane, it specifically orients so that the cyano group lean towards the phospholipid interface and it specifically interacts with particular phospholipids. Significantly, in the membrane the CDDO-Me molecules specifically interact with POPE and POPS. Moreover, CDDO-Me does not aggregates in the membrane but it forms a complex conglomerate in solution. The formation of a complex aggregate in solution might hamper its biological activity and therefore it should be taken into account when intended to be used in clinical assays. This work should aid in the development of these molecules opening new avenues for future therapeutic developments.

Entities:  

Keywords:  Bardoxolone methyl; CDDO-me; Membrane location; Molecular dynamics

Mesh:

Substances:

Year:  2020        PMID: 31965219     DOI: 10.1007/s00232-020-00106-5

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  50 in total

1.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes.

Authors:  T Utsugi; A J Schroit; J Connor; C D Bucana; I J Fidler
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Authors:  Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

Review 3.  A computer perspective of membranes: molecular dynamics studies of lipid bilayer systems.

Authors:  D P Tieleman; S J Marrink; H J Berendsen
Journal:  Biochim Biophys Acta       Date:  1997-11-21

4.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

5.  Quercetin and epigallocatechin gallate effects on the cell membranes biophysical properties correlate with their antioxidant potential.

Authors:  Denisa Margina; Mihaela Ilie; Gina Manda; Ionela Neagoe; Magdalena Mocanu; Diana Ionescu; Daniela Gradinaru; Constanţa Ganea
Journal:  Gen Physiol Biophys       Date:  2012-03       Impact factor: 1.512

6.  Bardoxolone methyl prevents obesity and hypothalamic dysfunction.

Authors:  Danielle Camer; Yinghua Yu; Alexander Szabo; Hongqin Wang; Chi H L Dinh; Xu-Feng Huang
Journal:  Chem Biol Interact       Date:  2016-07-11       Impact factor: 5.192

7.  Geometrical effects of phospholipid olefinic bonds on the structure and dynamics of membranes: A molecular dynamics study.

Authors:  Hui-Hsu Gavin Tsai; Jian-Bin Lee; Hung-Sheng Li; Tsai-Yi Hou; Wen-Yuan Chu; Po-Chuan Shen; Ying-Yu Chen; Chun-Jui Tan; Jia-Cheng Hu; Chih-Chiang Chiu
Journal:  Biochim Biophys Acta       Date:  2015-02-28

8.  A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Authors:  David S Hong; Razelle Kurzrock; Jeffrey G Supko; Xiaoying He; Aung Naing; Jennifer Wheler; Donald Lawrence; Joseph Paul Eder; Colin J Meyer; Deborah A Ferguson; James Mier; Marina Konopleva; Sergej Konoplev; Michael Andreeff; Donald Kufe; Hillard Lazarus; Geoffrey I Shapiro; Bruce J Dezube
Journal:  Clin Cancer Res       Date:  2012-05-25       Impact factor: 12.531

9.  Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.

Authors:  Dorrah Deeb; Xiaohua Gao; Hao Jiang; Scott A Dulchavsky; Subhash C Gautam
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

10.  CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.

Authors:  K Vanommeslaeghe; E Hatcher; C Acharya; S Kundu; S Zhong; J Shim; E Darian; O Guvench; P Lopes; I Vorobyov; A D Mackerell
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.